WEBSITE BSE:0 NSE: Inc. Year: 2021 Industry: Hospital & Healthcare Services My Bucket: Add Stock
Last updated: 15:19
No Notes Added Yet
Sangani Hospitals Limited is a healthcare provider based in India, dedicated to delivering quality medical services across various specialties. Established with a vision to enhance patient care, the hospital is equipped with state-of-the-art facilities and advanced medical technology. It offers a wide range of services, including emergency care, surgical procedures, diagnostic services, and outpatient treatments. The hospital prides itself on its team of experienced healthcare professionals, including doctors, nurses, and support staff, who are...Read More
Sangani Hospitals Limited is a healthcare provider based in India, dedicated to delivering quality medical services across various specialties. Established with a vision to enhance patient care, the hospital is equipped with state-of-the-art facilities and advanced medical technology. It offers a wide range of services, including emergency care, surgical procedures, diagnostic services, and outpatient treatments. The hospital prides itself on its team of experienced healthcare professionals, including doctors, nurses, and support staff, who are committed to ensuring patient safety and comfort. Sangani Hospitals emphasizes personalized care, focusing on individual patient needs and treatment plans. The institution is also involved in community health initiatives, promoting wellness and preventive care. With a patient-centered approach, Sangani Hospitals Limited aims to be a leading healthcare provider, contributing to the overall well-being of the communities it serves. ...Read Less
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹71 Cr.
Stock P/E 27.4
P/B 2
Current Price ₹51.5
Book Value ₹ 26.2
Face Value 10
52W High ₹77
Dividend Yield 0%
52W Low ₹ 37
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) |
|---|
| Net Sales |
| Other Income |
| Total Income |
| Total Expenditure |
| Operating Profit |
| Interest |
| Depreciation |
| Exceptional Income / Expenses |
| Profit Before Tax |
| Provision for Tax |
| Profit After Tax |
| Adjustments |
| Profit After Adjustments |
| Adjusted Earnings Per Share |
| #(Fig in Cr.) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|
| Net Sales | 4 | 16 | 16 | 21 | |
| Other Income | 0 | 0 | 1 | 2 | |
| Total Income | 4 | 16 | 17 | 23 | |
| Total Expenditure | 3 | 13 | 13 | 19 | |
| Operating Profit | 1 | 3 | 4 | 4 | |
| Interest | 0 | 0 | 0 | 0 | |
| Depreciation | 0 | 1 | 0 | 1 | |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | |
| Profit Before Tax | 1 | 2 | 4 | 3 | |
| Provision for Tax | 0 | 1 | 1 | 1 | |
| Profit After Tax | 1 | 2 | 3 | 3 | |
| Adjustments | 0 | 0 | 0 | 0 | |
| Profit After Adjustments | 1 | 2 | 3 | 3 | |
| Adjusted Earnings Per Share | 2.7 | 1.5 | 2 | 1.9 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 31% | 74% | 0% | 0% |
| Operating Profit CAGR | 0% | 59% | 0% | 0% |
| PAT CAGR | 0% | 44% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -30% | NA% | NA% | NA% |
| ROE Average | 7% | 10% | 13% | 13% |
| ROCE Average | 10% | 14% | 17% | 17% |
| #(Fig in Cr.) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Shareholder's Funds | 5 | 18 | 33 | 36 |
| Minority's Interest | 0 | 0 | 0 | 0 |
| Borrowings | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 1 |
| Total Current Liabilities | 2 | 1 | 1 | 2 |
| Total Liabilities | 7 | 20 | 35 | 39 |
| Fixed Assets | 1 | 12 | 13 | 13 |
| Other Non-Current Assets | 0 | 0 | 0 | 3 |
| Total Current Assets | 6 | 8 | 22 | 23 |
| Total Assets | 7 | 20 | 35 | 39 |
| #(Fig in Cr.) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 2 | 3 | 4 | 19 |
| Cash Flow from Operating Activities | -0 | 3 | 3 | 2 |
| Cash Flow from Investing Activities | -0 | -12 | -1 | -1 |
| Cash Flow from Financing Activities | 1 | 11 | 12 | -2 |
| Net Cash Inflow / Outflow | 1 | 1 | 15 | -1 |
| Closing Cash & Cash Equivalent | 3 | 4 | 19 | 18 |
| # | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Earnings Per Share (Rs) | 2.67 | 1.53 | 1.96 | 1.88 |
| CEPS(Rs) | 2.74 | 2.61 | 2.16 | 2.31 |
| DPS(Rs) | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 12.71 | 18.02 | 24.31 | 26.19 |
| Core EBITDA Margin(%) | 34.47 | 19.29 | 19.82 | 11.57 |
| EBIT Margin(%) | 33.79 | 13.06 | 23.38 | 16.34 |
| Pre Tax Margin(%) | 33.79 | 13.06 | 23.17 | 16.34 |
| PAT Margin (%) | 25.05 | 9.78 | 17.2 | 12.24 |
| Cash Profit Margin (%) | 25.76 | 16.6 | 19.02 | 15.05 |
| ROA(%) | 14.93 | 11.49 | 9.8 | 6.95 |
| ROE(%) | 21 | 13.32 | 10.48 | 7.46 |
| ROCE(%) | 26.25 | 17.42 | 14.19 | 9.93 |
| Receivable days | 203.42 | 54.76 | 53.66 | 44.8 |
| Inventory Days | 22.01 | 9.75 | 15.81 | 16.36 |
| Payable days | 454.87 | 43.37 | 60.37 | 51.85 |
| PER(x) | 0 | 0 | 21.71 | 37.92 |
| Price/Book(x) | 0 | 0 | 1.75 | 2.73 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 0.29 | 0.36 | 2.52 | 3.79 |
| EV/Core EBITDA(x) | 0.84 | 1.8 | 9.99 | 19.79 |
| Net Sales Growth(%) | 0 | 272.6 | 0.05 | 35.14 |
| EBIT Growth(%) | 0 | 44.06 | 79.06 | -5.55 |
| PAT Growth(%) | 0 | 45.41 | 76.05 | -3.82 |
| EPS Growth(%) | 0 | -42.5 | 27.59 | -3.82 |
| Debt/Equity(x) | 0.08 | 0.01 | 0 | 0 |
| Current Ratio(x) | 3.79 | 5.4 | 15.09 | 9.62 |
| Quick Ratio(x) | 3.63 | 4.99 | 14.56 | 9.15 |
| Interest Cover(x) | 0 | 0 | 113.82 | 0 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 |
| # | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoter | 73.04 | 73.22 | 73.22 | 73.22 | 73.22 | 73.22 | 73.22 | 74.09 |
| FII | 0 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 26.96 | 26.76 | 26.76 | 26.76 | 26.76 | 26.76 | 26.78 | 25.91 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoter | 1.01 | 1.01 | 1.01 | 1.01 | 1.01 | 1.01 | 1.01 | 1.02 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 0.37 | 0.37 | 0.37 | 0.37 | 0.37 | 0.37 | 0.37 | 0.36 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1.38 | 1.38 | 1.38 | 1.38 | 1.38 | 1.38 | 1.38 | 1.38 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
ChatGPT
Claude
Perplexity
